Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients Single-arm phase II trials may not be appropriate for testing cytostatic ...
Generally, the randomization for phase II trials is between two regimens, tumor response is the end point of interest, and the goal is to determine whether one experimental regimen should be brought ...
All clinicians face the challenge of practicing evidence-based medicine and are confronted with data from a variety of studies, ranging from prospective randomized and registry studies to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results